[go: up one dir, main page]

WO2025012295A1 - Utilisation d'acide l-glutamique et/ou d'un sel de celui-ci - Google Patents

Utilisation d'acide l-glutamique et/ou d'un sel de celui-ci Download PDF

Info

Publication number
WO2025012295A1
WO2025012295A1 PCT/EP2024/069418 EP2024069418W WO2025012295A1 WO 2025012295 A1 WO2025012295 A1 WO 2025012295A1 EP 2024069418 W EP2024069418 W EP 2024069418W WO 2025012295 A1 WO2025012295 A1 WO 2025012295A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
acid
glutamic acid
salt
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/069418
Other languages
English (en)
Inventor
Angharad Ellen GREEN
Sally Gillian Grimshaw
Jason Peter Harcup
Michael John Hoptroff
Joanne Elizabeth HUNT
Barry Gerard MURPHY
Polliana MENDES CANDIA SCAFFA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Original Assignee
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Global IP Ltd, Unilever IP Holdings BV, Conopco Inc filed Critical Unilever Global IP Ltd
Publication of WO2025012295A1 publication Critical patent/WO2025012295A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to the use of L-glutamic acid, and/or a salt thereof, for increasing the biosynthesis of GABA by resident skin commensal microbes on the skin of an individual.
  • the stratum corneum contains layers of corneocytes embedded in a lipid matrix which is made up of a unique complex mixture of polar and nonpolar lipids that, unlike biological membranes, is almost devoid of phospholipids. Its main components are ceramides, cholesterol, and free fatty acids (predominantly long-chain and saturated) which are organized into specific lamellar structures whose integrity depends not only on the quality of the fractions present but also on their respective proportions.
  • GABA Gamma-aminobutyric acid
  • GABA may play multiple beneficial roles in skin, such as inter alia stimulating the synthesis of hyaluronic acid (HA), controlling the balance between the synthesis and degradation of type I collagen, accelerating skin barrier repair, and regulating skin barrier homeostasis.
  • HA hyaluronic acid
  • the present invention addresses this problem. of the Invention
  • the invention provides the cosmetic use of L-glutamic acid, and/or a salt thereof, in a cosmetic skin care composition as an active ingredient for enhancing GABA biosynthesis by resident skin commensal microbes on the skin of an individual.
  • the invention also provides L-glutamic acid, and/or a salt thereof, for use in enhancing GABA biosynthesis by resident skin commensal microbes on the skin of an individual.
  • cosmetic skin care means regulating and/or improving cosmetic qualities of the skin, as opposed to curing, treating, or preventing a disease or disorder. Accordingly, such cosmetic qualities are subject to regulation and/or improvement both in healthy subjects as well as those which present diseases or disorders of the skin such as psoriasis, lichen planus, folliculitis, or atopic dermatitis.
  • cosmetic skin care benefits in the context of this invention include providing a smoother, more even texture; improving the elasticity or resiliency of the skin; improving the firmness of the skin; improving the hydration status or moisturization of the skin; improving skin barrier properties; and reducing the appearance of redness or skin blotches.
  • skin is understood as the layers which comprise it, from the uppermost layer or stratum corneum to the lowermost layer or hypodermis, both inclusive. These layers are composed of different types of cells such as keratinocytes, fibroblasts, melanocytes, mastocytes, neurons, and adipocytes. The term “skin” also comprises the scalp.
  • the term “resident skin commensal” denotes a microbe which can normally be found on healthy human skin, whose interactions on the skin are either neutral or beneficial, and which are permanent inhabitants on the surface of the skin, the stratum corneum and within the outer layer of the epidermis and the deeper crevices of the skin and hair follicles. Microbial colonization is differentially shaped by the physiological and topological variation of the skin, and varies systematically among different skin habitats, such as between dry, moist, and sebaceous skin. Resident skin commensal microbes are characterized in that they can grow and multiply on the skin without invading or damaging the skin tissue. Another characteristic of these microbes is that washing does not easily remove them in deeper skin regions.
  • L-glutamic acid and/or a salt thereof is used for enhancing GABA biosynthesis by resident skin commensal microbes on the skin of an individual.
  • L-Glutamic acid (L-2-amino-pentanedioic acid) has the following structural formula (I):
  • Salts of L-glutamic acid may suitably correspond to the following structural formula (II): in which n is 1 or 2.
  • Suitable counterions X include ammonium, or an alkali metal such as sodium or potassium, or an alkaline earth metal such as calcium or magnesium.
  • L-glutamic acid of formula (I) is preferred for use in the invention.
  • Examples of resident skin commensal microbes in the context of this invention are members of the species Cutibacterium acnes, especially C. acnes subspecies defendens (phylotype II) strains (RT2 and RT6).
  • C. acnes The members of the species C. acnes have been classified into three major genetic lineages, (phylotypes, I, II, and III) based on serological agglutination tests, cell wall sugar analysis, fatty acid profiles, and morphology. These have been assigned to three subspecies as follows: phylotype I as C. acnes subsp. acnes, phylotype II as C. acnes subsp. defendens, and phylotype III as C. acnes subsp. elongatum. Based on 16S rRNA gene analysis, C. acnes strains have also been classified into multiple ribotypes (RTs).
  • RTs ribotypes
  • C. acnes subspecies acnes (phylotype I) strains (RT1 , RT3, RT4, RT5, and RT8) are more often associated with acne.
  • C. acnes subspecies defendens (phylotype II) strains (RT2 and RT6) are more frequently found on healthy skin, particular the RT6 subgroup which has been found to be 99% associated with healthy skin.
  • C. acnes subsp. defendens (phylotype II) strains associated with healthy skin display a number of strain specific characteristics at the genetic, transcriptional, and translational levels, which may account for their commensal phenotype and non-association with acne. Elements that may be used to characterise such strains include the presence of a complete set of the CRISPR/Cas genes. Also, C. acnes subsp. defendens (phylotype II) strains associated with healthy skin secrete only low levels of porphyrins and carry a deoR gene that represses porphyrin biosynthesis.
  • compositions for use in the invention can be formulated in a variety of forms for topical application and will generally contain from about 0.01 to about 10%, preferably from about 0.1 to about 5% of L-glutamic acid and/or a salt thereof (by weight based on the total weight of the composition).
  • at least 75%, more preferably at least 85%, and most preferably 100% of the L- glutamic acid and/or salt thereof in said composition is L-glutamic acid (by weight based on the total weight of the L-glutamic acid and/or salt thereof).
  • Topical compositions for use in the invention will generally include a cosmetically acceptable vehicle.
  • Cosmetically acceptable means that the vehicle is suitable for topical application to the skin, has good aesthetic properties, is compatible with the L-glutamic acid and/or salt thereof, and any other ingredients, and will not cause any safety or toxicity concerns.
  • the vehicle may comprise an aqueous phase, an oil phase, an alcohol, a silicone phase, or a mixture thereof, and may be in the form of an emulsion.
  • Emulsions can have a range of consistencies including thin lotions (which may also be suitable for spray or aerosol delivery), creamy lotions, light creams, and heavy creams.
  • Exemplary emulsions include water-in-oil emulsions, oil-in-water emulsions, silicone-in-water emulsions, water-in-silicone emulsions, polyol-in-silicone emulsions, silicone-in-polyol emulsions, polyol-in-oil emulsions, oil-in-polyol emulsions, wax-in-water emulsions, and water- oil-water triple emulsions.
  • Preferred emulsions include oil-in-water emulsions and water-in-oil emulsions.
  • Topical cosmetic compositions in the form of an emulsion, and suitable for use in the invention typically have an oil phase containing at one or more cosmetically acceptable fatty materials which may be liquid or solid at room temperature (25°C).
  • Suitable cosmetically acceptable fatty materials include naturally derived oils (such as sunflower oil, borage oil, soybean oil, castor oil, olive oil and almond oil); esters of monoalcohols or of glycols with monocarboxylic or polycarboxylic acids, at least one of the alcohols and/or acids comprising at least one hydrocarbon-based chain containing at least 6 carbon atoms (such as octyl palmitate, isopropyl myristate, isopropyl palmitate, isopropyl isostearate, hexyl laurate, isohexyl laurate, isohexyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, dihexyldecyl adipate, lauryl lactate, myristyl lactate, cetyl lactate, oleyl stearate, oleyl oleate
  • Topical cosmetic compositions in the form of an emulsion, and suitable for use in the invention typically have an aqueous phase, with the amount of water in such an emulsion suitably ranging from about 5 to about 95%, preferably from about 35 to about 80% (by weight based on the total weight of the composition).
  • the aqueous phase may also include one or more organic liquids that are miscible with water at room temperature (25°C).
  • Exemplary water-miscible organic liquids include monohydric and polyhydric alcohols and derivatives thereof such as C2- C 6 alkanols (such as ethanol and isopropanol); C2-C10 glycols and polyols (such as glycerol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, caprylyl glycol, dipropylene glycol, and diethylene glycol); C3-C16 glycol ethers (such as mono-, di-, or tripropylene glycol (C1-C4) alkyl ethers and mono-, di-, or triethylene glycol (C1-C4) alkyl ethers) and polyethylene glycol having 2 to 12 oxyethylene units.
  • C2- C 6 alkanols such as ethanol and isopropanol
  • C2-C10 glycols and polyols such as glycerol, propylene glycol, butylene glycol, pentylene
  • Topical cosmetic compositions in the form of an emulsion, and suitable for use in the invention generally include emulsifiers and solubilizers, to enable two or more immiscible components to be combined homogeneously and to help stabilize the composition.
  • the amount of emulsifier and solubilizer in such an emulsion suitably ranges from about 0.1 to about 30%, preferably from about 1 to about 8% (by weight based on the total weight of the composition).
  • Emulsifiers that may be used to form O/W or W/O emulsions include sorbitan oleate, sorbitan sesquioleate, sorbitan isostearate, sorbitan trioleate, PEG-20 sorbitan isostearate, polyglyceryl-3- di isostearate, polyglycerol esters of oleic/isostearic acid, polyglyceryl-6 hexaricinolate, polyglyceryl-4-oleate, polyglyceryl-4 oleate/PEG-8 propylene glycol cocoate, polyglyceryl-2 dipolyhydroxystearate, PEG-30 dipolyhydroxystearate, oleamide DEA, TEA myristate, TEA stearate, magnesium stearate, sodium stearate, potassium laurate, potassium ricinoleate, sodium cocoate, sodium tallowate, potassium castorate, sodium oleate, cetyl phosphate, diethanol
  • Topical cosmetic compositions suitable for use in the invention may also take the form of a skin cleanser incorporating one or more cleansing surfactants which, when combined with water and mechanically agitated, generate a foam or lather.
  • the amount of cleansing surfactant suitably ranges from about 5 to about 40%, preferably from about 10 to about 35% (by weight based on the total weight of the composition).
  • Exemplary cleansing surfactants include anionic surfactants such as ammonium lauroyl sarcosinate, sodium trideceth sulfate, sodium lauroyl sarcosinate, sodium myristoyl sarcosinate, ammonium laureth sulfate, sodium laureth sulfate, ammonium lauryl sulfate, sodium lauryl sulfate, ammonium cocoyl isethionate, sodium cocoyl isethionate, sodium lauroyl isethionate, sodium cocoyl glycinate, sodium lauroyl glycinate, sodium lauroyl taurate, sodium methyl lauroyl taurate, sodium methyl oleoyl taurate, sodium cetyl sulfate, sodium lauroyl lactylate and triethanolamine lauroyl lactylate and mixtures thereof; nonionic surfactants such as lauramine oxide, cocoamine oxide, decyl polyglucose,
  • Topical cosmetic compositions for use in the invention may also be formulated in a single-phase carrier such as water and/or one or more water miscible organic liquids (such as the monohydric and polyhydric alcohols and derivatives thereof described above).
  • a single-phase carrier such as water and/or one or more water miscible organic liquids (such as the monohydric and polyhydric alcohols and derivatives thereof described above).
  • Topical cosmetic compositions for use in the invention may also be formulated in solid forms such as gels or sticks.
  • a topical cosmetic composition for use in the invention may include additional skin care actives (for improving the physical and/or aesthetic characteristics of the skin).
  • additional skin care actives which are suitable for use in the invention include vitamins, minerals and/or antioxidants, emollients, humectants, skin anti-hyperpigmentation agents, sunscreens, anti-irritants, exfoliating agents, and mixtures thereof.
  • Vitamins, minerals and/or antioxidants suitable for use in the invention include natural botanical antioxidants derived from plant materials such as fruits, vegetables, herbs and spices (such as goji berry, white tea, rosemary, green tea, grape seed and lemongrass extracts); vitamin A and its precursors or derivatives (such as beta-carotene, retinyl palmitate); vitamin B3 and its precursors or derivatives (such as niacinamide); vitamin B5 and its precursors or derivatives (such as panthenol and its precursors or derivatives); vitamin C and its precursors or derivatives (such as tetrahexyldecyl ascorbate, ascorbyl palmitate); vitamin E and its precursors or derivatives (such as d-alpha-tocopherol, tocopheryl acetate); vitamin K and its precursors or derivatives; selenium and its derivatives (such as L-selenomethionine); and alpha lipoic acid.
  • natural botanical antioxidants derived from plant materials such as fruits, vegetables,
  • Emollients suitable for use in the invention act to increase and maintain moisture in the skin by providing a protective coating to impede epidermal water loss.
  • emollients include C10-20 fatty alcohols and acids (such as cetyl, myristyl, palmitic and stearyl alcohols and acids); and C10-40 hydrocarbons (such as mineral oil, petroleum jelly, squalene and isoparaffins).
  • Humectants suitable for use in the invention act to increase and maintain moisture in the skin by attracting water to the stratum corneum of the epidermis.
  • humectants include amino acids, chondroitin sulfate, glycerin, diglycerin, triglycerin, polyglycerin, polypropylene glycol, polyethylene glycol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, hexylene glycol, 1 ,3-butylene glycol, 1,4-butylene glycol, ethylene glycol monoalkyl ether, diethylene glycol monoalkyl ether, erythritol, fructose, glucose, maltose, sucrose, lactose, xylose, inositol, lactitol, xylitol, sorbitol, mannitol, maltitol, panthenol, penta
  • Skin anti-hyperpigmentation agents suitable for use in the invention include natural botanical agents derived from plant materials (such as Arctostaphylos patula and Arctostaphylos viscida extracts, Emblica officinalis extract, Mitracarpus sea ber extract, Uva ursi (bearberry) extract, Morus bombycis (mulberry) extract, Morus alba (white mulberry) extract, Broussonetia papyrifera (paper mulberry) extract, licorice extract, acerola cherry extract, Chlorella vulgaris extract, Aloe ferrox extract and Rumex occidentalis extract); synthetic or natural sugar amines (such as glucosamine, N-acetyl glucosamine, glucosamine sulfate, mannosamine, N- acetyl mannosamine, galactosamine, N-acetyl galactosamine and their hydrochloride salts); retinoids (such as retinol, retinal,
  • Sunscreens suitable for use in the invention protect the skin from ultraviolet (UV) solar radiation falling within both the UVB region (between 290nm to 320 nm wavelengths) and the UVA region (between 320nm and 400nm wavelengths).
  • sunscreens include methoxycinnamate derivatives (such as octyl methoxycinnamate and isoamyl methoxycinnamate); camphor derivatives (such as 4-methyl benzylidene camphor, camphor benzalkonium methosulfate, and terephthalylidene dicamphor sulfonic acid); salicylate derivatives (such as octyl salicylate and homosalate); sulfonic acid derivatives (such as phenylbenzimidazole sulfonic acid); benzone derivatives (such as dioxybenzone, sulisobenzone, and oxybenzone); benzoic acid derivatives (such as aminobenzoic acid and octyld
  • Anti-irritants suitable for use in the invention include allantoin, aloe vera, a-bisabolol, caffeine, chamomile extract, Cola nitada extract, cucumber extract, dipotassium glycyrrhizinate, glycyrrhizic acid, green tea extract, lecithin or hydrogenated lecithin, licorice extract, Avena sativa (oat) meal extract, tea tree oil, salicylic acid, acetylsalicylic acid, strontium acetate, strontium chloride, strontium nitrate, fatty acids with anti-irritant properties (such as linoleic acid and linolenic acid) and aromatic aldehydes with anti-irritant properties (such as 4-methoxy benzaldehyde, 4-ethoxy benzaldehyde, 4-butoxy benzaldehyde and 4-pentoxy benzaldehyde).
  • Exfoliating agents suitable for use in the invention include benzoyl peroxide, benzoic acid, 3- hydroxy benzoic acid, salicylic acid, acetic acid, trichloroacetic acid, 1 -pyrrolidone- 5-carboxylic acid, a-hydroxy acids (such as glycolic acid, lactic acid, malic acid, tartaric acid, and citric acid); P-hydroxy acids (such as p-hydroxybutyric acid); a-keto acids (such as pyruvic acid, 2- oxopropanoic acid, 2-oxobutanoic acid and 2-oxopentanoic acid); and oxa acids (such as 3,6,9- trioxaundecanedioic acid).
  • a-hydroxy acids such as glycolic acid, lactic acid, malic acid, tartaric acid, and citric acid
  • P-hydroxy acids such as p-hydroxybutyric acid
  • a-keto acids such as pyruvic acid, 2- oxopropa
  • a topical cosmetic composition for use in the invention may include additional functional ingredients (for improving the physical and/or aesthetic characteristics of the composition).
  • water soluble or colloidally water soluble polymeric thickening agents such as hydroxyethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, polyquaternium-10, carrageenan, guar gum, hydroxypropyl guar gum, xanthan gum, polyvinylalcohol, acrylic acid/ethyl acrylate copolymers, carboxyvinyl polymers, cross-linked polyacrylate polymers and polyacrylamide polymers
  • structurant clays such as magnesium aluminum silicate, attapulgite, bentonite, montmorillonite and hectorite
  • inorganic pigments such as titanium oxide, zirconium oxide, cerium oxide zinc oxide, iron oxide, chromium oxide and ferric blue
  • organic pigments such as carbon black and barium, strontium, calcium, and aluminium lakes
  • pearlescent agents such as mica coated with titanium oxide and/or iron oxide
  • dyes, preservatives such as hydroxyethyl cellulose, methyl
  • the topical cosmetic composition for use in the invention may be packaged in a suitable container to suit its viscosity and intended use by the consumer.
  • a lotion or a cream can be packaged in a bottle or a roll-ball applicator, or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation.
  • the composition is a cream, it can simply be stored in a non-deformable bottle or sgueeze container, such as a tube or a lidded jar.
  • the topical cosmetic composition for use in the invention may suitably be applied to the skin at the rate of one or two applications per day.
  • an amount corresponding to about 1 to 2 ml of the composition per application is applied uniformly over the area of treatment twice daily for a period of at least 7 (seven) days, preferably at least 30 (thirty) days.
  • An ELISA kit was used to measure the biosynthesis of GABA, when L-glutamic acid was used as substrate, by two different test strains of Cutibacterium acnes’. one associated with healthy skin (1) and the other associated with acne (2) .
  • Cutibacterium acnes subsp. defendens ATCC 11828 (phylotype II, ribotype RT2)
  • Test bacterial inoculums were prepared in recommended growth media for up 48 hours at 37°C under anaerobic conditions. Inoculums were centrifuged and resuspended in liquid media diluted to 25% in sterile distilled water. The inoculums were adjusted to an optical density (OD) at 600nm of 1. As a substrate, 8mg/ml of L-glutamic acid solution was prepared in 25% media.
  • Tested conditions were prepared and incubated for 24h at 37 °C shaking. For that, 5ml of each isolate at OD 1 was added to 5ml of 8mg/ml L-glutamic acid (substrate). Controls were prepared where no substrate (only isolates in media) and substrate (only L-glutamic acid in media) were included in the assay.
  • an ELISA kit was used to measure the amount of GABA production (ab287792 - Human QuickDetectTM GABA ELISA Kit, from Abeam pic, Cambridge UK), by following manufacturer’s instructions.
  • Table 1 shows the amount of GABA produced by the tested bacterial species after incubation with the substrate L-Glutamic-acid, compared to the controls.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne l'utilisation cosmétique d'acide L-glutamique, et/ou d'un sel de celui-ci, dans une composition cosmétique de soin de la peau en tant que principe actif pour améliorer la biosynthèse de GABA par des microbes commensaux cutanés résidents sur la peau d'un individu. L'invention concerne également de l'acide L-glutamique, et/ou un sel de celui-ci, destiné à être utilisé dans l'amélioration de la biosynthèse de GABA par des microbes commensaux cutanés résidents sur la peau d'un individu.
PCT/EP2024/069418 2023-07-13 2024-07-09 Utilisation d'acide l-glutamique et/ou d'un sel de celui-ci Pending WO2025012295A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23185375 2023-07-13
EP23185375.5 2023-07-13

Publications (1)

Publication Number Publication Date
WO2025012295A1 true WO2025012295A1 (fr) 2025-01-16

Family

ID=87280626

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2024/069417 Pending WO2025012294A1 (fr) 2023-07-13 2024-07-09 Procédés de soins cosmétiques de la peau
PCT/EP2024/069418 Pending WO2025012295A1 (fr) 2023-07-13 2024-07-09 Utilisation d'acide l-glutamique et/ou d'un sel de celui-ci

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/069417 Pending WO2025012294A1 (fr) 2023-07-13 2024-07-09 Procédés de soins cosmétiques de la peau

Country Status (1)

Country Link
WO (2) WO2025012294A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024011A1 (fr) * 1997-11-07 1999-05-20 Howard Murad Compositions pharmaceutiques stables comprenant de l'acide ascorbique et procedes se rapportant a leur utilisation
JP5558728B2 (ja) * 2008-03-12 2014-07-23 株式会社 資生堂 皮膚外用組成物
CN109431918A (zh) * 2018-12-30 2019-03-08 浙江因兆艾生物科技有限公司 一种皮肤屏障受损修复补水面膜及其制备方法
US20230172825A1 (en) * 2021-12-03 2023-06-08 Nature In Lab. Inc. Composition for improving skin comprising amino acid complex as active ingredient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006256966A (ja) * 2005-03-15 2006-09-28 Shiseido Co Ltd 皮膚外用組成物
JP2007169167A (ja) * 2005-12-19 2007-07-05 Shiseido Co Ltd Ｃｅ形成・成熟化剤、不全角化阻害剤、皮膚バリアー機能回復促進剤およびスキンケア用皮膚外用組成物
EP2255780A1 (fr) * 2008-03-12 2010-12-01 Shiseido Company, Ltd. Inhibiteur de la parakératose, agent de rétrécissement des pores ou agent pour prévenir ou améliorer une rugosité de l'épiderme et composition les contenant pour un usage externe sur la peau
CN102365086A (zh) * 2009-03-30 2012-02-29 株式会社资生堂 紫外线损伤减轻用组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024011A1 (fr) * 1997-11-07 1999-05-20 Howard Murad Compositions pharmaceutiques stables comprenant de l'acide ascorbique et procedes se rapportant a leur utilisation
JP5558728B2 (ja) * 2008-03-12 2014-07-23 株式会社 資生堂 皮膚外用組成物
CN109431918A (zh) * 2018-12-30 2019-03-08 浙江因兆艾生物科技有限公司 一种皮肤屏障受损修复补水面膜及其制备方法
US20230172825A1 (en) * 2021-12-03 2023-06-08 Nature In Lab. Inc. Composition for improving skin comprising amino acid complex as active ingredient

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GNPD [online] MINTEL; 12 October 2009 (2009-10-12), ANONYMOUS: "Serum", XP093108681, retrieved from https://www.gnpd.com/sinatra/recordpage/1193445/ Database accession no. 1193445 *
FUZIWARA SHIGEYOSHI ET AL: "NMDA-type glutamate receptor is associated with cutaneous barrier homeostasis", JOURNAL OF INVESTIGATIVE DERMATOLOGY, ELSEVIER, NL, vol. 120, no. 6, 1 June 2003 (2003-06-01), pages 1023 - 1029, XP009151696, ISSN: 0022-202X *
PIERRE-JEAN RACINE ET AL: "Dialog between skin and its microbiota: Emergence of "Cutaneous Bacterial Endocrinology"", EXPERIMENTAL DERMATOLOGY, BLACKWELL MUNSGAARD, COPENHAGEN; DK, vol. 29, no. 9, 3 August 2020 (2020-08-03), pages 790 - 800, XP071779415, ISSN: 0906-6705, DOI: 10.1111/EXD.14158 *

Also Published As

Publication number Publication date
WO2025012294A1 (fr) 2025-01-16

Similar Documents

Publication Publication Date Title
JP2004067675A (ja) 少なくとも１つの無水マレイン酸コポリマーによって安定化された、少なくとも１つの酸化感受性親水性有効成分を含む組成物の、美容及び／または皮膚科のための使用
TW200408411A (en) Cosmetic and/or dermatological use of a composition comprising at least one oxidation -sensitive hydrophilic active principle stabilized by at least one N-vinylimidazole polymer or copolymer
CA3046137A1 (fr) Additif topique d'eclaircissement de la peau et composition comprenant des acides amines et des acides gras activant les ppar
EP2305212A1 (fr) Composition contenant un extrait de bactérie filamenteuse et procédé de traitement cosmétique des signes du vieillissement
FR2942962A1 (fr) Utilisation d'une dihydrochalcone ou l'un de ses derives pour ameliorer l'etat de surface d'une peau fragilisee et/ou alteree
US20100074965A1 (en) Cosmetic composition comprising a meteorite extract, and use of the extract as cosmetic agent suitable for stimulating the differentiation of human keratinocytes
ES2628085T3 (es) Composiciones tópicas que contienen cis-6-nonenol y sus derivados y métodos para tratar la piel
WO2025012295A1 (fr) Utilisation d'acide l-glutamique et/ou d'un sel de celui-ci
WO2025252619A1 (fr) Méthodes cosmétiques pour soins de la peau
WO2025021434A1 (fr) Compositions cosmétiques pour maintenir et restaurer la fonction de barrière cutanée
WO2025252618A1 (fr) Méthodes de soins cosmétiques de la peau
WO2024223321A1 (fr) Compositions cosmétiques pour maintenir et restaurer la fonction de barrière cutanée
WO2024223320A1 (fr) Compositions cosmétiques pour maintenir et restaurer la fonction de barrière cutanée
WO2024223319A1 (fr) Compositions cosmétiques pour maintenir et restaurer la fonction de barrière cutanée
WO2025113965A1 (fr) Utilisation de l-aspartate pour améliorer la production de pantothénate
WO2025114094A1 (fr) Utilisation de l-aspartate
WO2025114095A1 (fr) Utilisation de l-valine pour augmenter la biosynthèse de nicotinamide riboside
EP4167943A1 (fr) Utilisation de composés d'indole pour traiter les signes du vieillissement de la peau
WO2021254752A1 (fr) Utilisation de composés de diindolylméthane pour traiter les signes du vieillissement cutané
WO2022184763A1 (fr) Utilisation de galacto-oligosaccharides pour procurer des bienfaits à la peau
EP4308247B1 (fr) Utilisation de monoglycérides pour traiter les signes de vieillissement de la peau
EP4218713A1 (fr) Utilisation d'une composition topique de soins de la peau pour améliorer la biosynthèse des lipides de la couche cornée
EP4218712A1 (fr) Utilisation d'une composition topique de soins de la peau d'enrichissement sélectif de microbes commensaux dermiques résidents
US20250049679A1 (en) Formulations of eriodictyol
EP4168130B1 (fr) Utilisation de composés d'indole pour traiter les signes de vieillissement de la peau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24743718

Country of ref document: EP

Kind code of ref document: A1